Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas

Core Insights - Abeona Therapeutics Inc. has activated The University of Texas Medical Branch (UTMB) as a Qualified Treatment Center (QTC) for ZEVASKYN, a gene-modified cellular therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB) [1][3] Company Overview - Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, with ZEVASKYN being the first autologous cell-based gene therapy for RDEB [10] - The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio, which is responsible for the commercial production of ZEVASKYN [10] Product Information - ZEVASKYN (prademagene zamikeracel) is the first FDA-approved autologous gene therapy for RDEB, designed to treat chronic wounds by incorporating the COL7A1 gene into a patient's skin cells [5][6] - The therapy has shown clinically meaningful results in wound healing and pain reduction with a single surgical application [5] Treatment Center Activation - The activation of UTMB as a QTC significantly enhances patient access to ZEVASKYN across Texas and the Gulf Coast region, reflecting UTMB's commitment to innovative care [3] - UTMB is recognized for its expertise in complex skin diseases and wound care, making it an ideal partner for delivering ZEVASKYN [2][3] Patient Support Services - Abeona offers a comprehensive patient support program called Abeona Assist, which provides personalized assistance, including help with insurance benefits, financial options, and logistical support for patients [3]